ArticleFrontiers in medicine2026
Effectiveness and tolerability of cephalexin and clavulanic acid fixed dose combination, amoxicillin and clavulanic acid fixed dose combination, and azithromycin in patients with pharyngitis in India: a real-world retrospective study from electronic medical records (PHARYSPOR).
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pharyngitis is a common condition in outpatient departments. Increasing antimicrobial resistance (AMR) necessitates careful prescribing practices. A new fixed-dose combination (FDC) of cephalexin-clavulanate has been approved in India for bacterial infections. This real-world evidence (RWE) study assessed the effectiveness and tolerability of cephalexin-CV compared to co-amoxiclav FDC and azithromycin in adult patients with acute bacterial pharyngitis. Methods: This retrospective, multicenter, comparative observational study (CTRI/2023/08/056474; Registered on: 14 Aug 2023) analyzed aggregated and anonymized electronic medical records (EMRs) of adults with clinically suspected acute bacterial pharyngitis who received study medications between November 2022 and March 2023. Patients with incomplete records, hospitalizations, or requiring parenteral antibiotics were excluded. Primary outcomes included the proportion of patients achieving clinical cure, i.e., complete resolution of symptoms (fever, sore throat, throat pain/difficulty during swallowing, inflammation of tonsils, alone or in combination) by Day 10 from treatment initiation. Secondary outcomes included time to clinical improvement (partial symptomatic resolution at Days 2, 3, 5, and 7 from treatment initiation), non-steroidal anti-inflammatory drug (NSAID) requirements, addition or change in antibiotics, and reported adverse events (AEs). Results: The study analyzed 752 patient data treated with cephalexin-CV ( Conclusion: This first-of-its-kind EMR-based RWE study did not demonstrate any statistically significant differences in overall clinical outcomes or tolerability among patients with pharyngitis treated with cephalexin-CV, co-amoxiclav, or azithromycin. However, cephalexin-CV was associated with earlier symptom improvement and lower NSAID use, making it a promising option for the treatment of pharyngitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.